Isabel Kalofonos, Chief Commercial Officer of CG Oncology, Inc., filed a Form 4 on November 18, 2026, disclosing a purchase of 3,751 shares of common stock through a family trust at $79.755 per share.

Key Highlights

  • Reporting person: Isabel Kalofonos, Chief Commercial Officer of CG Oncology, Inc. (NASDAQ:CGON)
  • Transaction: Purchase (transaction code P) of 3,751 shares of common stock on November 18, 2026
  • Price per share: $79.755
  • Ownership structure: Shares are held indirectly by the Isabel Kalofonos Family Trust, of which the reporting person is a trustee
  • Resulting beneficial ownership: 3,751 shares beneficially owned following the reported transaction, held indirectly by the trust
  • Filing signatory: Joshua F. Patterson, Attorney-in-Fact for Isabel Kalofonos, signed the filing on November 18, 2026

Isabel Kalofonos Trust Purchase of CG Oncology Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Isabel Kalofonos, serving as Chief Commercial Officer of CG Oncology, Inc. (NASDAQ:CGON), reported the acquisition of 3,751 shares of the company's common stock on November 18, 2026. The transaction was coded as a purchase (code P), with each share acquired at a price of $79.755, as disclosed in the filing.

The filing states that the shares are held indirectly through the Isabel Kalofonos Family Trust, with the reporting person identified as a trustee of that trust. Following the reported transaction, the total amount of common stock beneficially owned by Kalofonos through this trust is listed as 3,751 shares. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. The document was signed by Joshua F. Patterson as Attorney-in-Fact for Isabel Kalofonos, with the signature dated November 18, 2026, the same date as the earliest reported transaction.

What Was Disclosed

CG Oncology's Chief Commercial Officer, Isabel Kalofonos, reported a purchase of 3,751 shares of common stock at $79.755 per share on November 18, 2026, held indirectly through the Isabel Kalofonos Family Trust, of which she is a trustee.